BWA
RLAY icon

Basecamp Wealth Advisors’s Relay Therapeutics RLAY Stock Holding History

Basecamp Wealth Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.66K Buy
356
+56
+19% +$813 ﹤0.01% 1110
2026
Q1 		$2.98K Buy
300
+9
+3% +$81 ﹤0.01% 1299
2025
Q4 		$2.46K Buy
+291
New +$2.08K ﹤0.01% 1309

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Basecamp Wealth Advisors's RLAY Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Relay Therapeutics (RLAY) stake by 19% in Q2 2026, buying an estimated $813 and bringing the position to 356 shares worth $6.66K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Basecamp Wealth Advisors first reported a position in RLAY in Q4 2025 and has held it in 3 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Basecamp Wealth Advisors held 356 shares of Relay Therapeutics worth $6.66K as of Q2 2026.
  • Basecamp Wealth Advisors bought 56 Relay Therapeutics shares in Q2 2026, an estimated $813.
  • Relay Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1110 holding.
  • Basecamp Wealth Advisors first reported a position in Relay Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.